PROCYTE CORPORATION – Trademark Portfolio
Entity Type: 03
PROCYTE CORPORATION holds 43 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 25 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include NEOVA and TRICOMIN. The owner is based in REDMOND, WA.
8511 - 154TH AVENUE NORTHEAST
REDMOND, WA 98052-355
Showing of trademarks Trademarks
Trademark Classifications
PROCYTE CORPORATION's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does PROCYTE CORPORATION have?
PROCYTE CORPORATION has 43 U.S. trademarks filed with the USPTO. Of these, 4 registered, 8 abandoned, 31 cancelled.
What trademark classes does PROCYTE CORPORATION file in?
PROCYTE CORPORATION files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 35 (Advertising & Business), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PROCYTE CORPORATION's most well-known trademarks?
PROCYTE CORPORATION's registered trademark portfolio includes well-known marks such as NEOVA and TRICOMIN. These are among 4 currently registered trademarks in the portfolio.
What is PROCYTE CORPORATION's trademark registration success rate?
PROCYTE CORPORATION has a 9% trademark registration rate, with 4 out of 43 resolved applications resulting in successful registration. Currently, 0 applications are pending review.